Raze Therapeutics

Raze Therapeutics is leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways. Raze is advancing a pipeline of therapeutics based on new biological insights into how cancer cells reprogram metabolism to activate central anabolic processes essential for tumors to grow and survive. Raze Therapeutics is based in Cambridge, MA.


Team Member
more about
Hakan Goker
Latest News Entry
Raze Therapeutics Announces Addition of Robert Copeland, PhD, to Scientific Advisory Board

Dr. Copeland brings deep experience in oncology drug discovery and development to Raze’s SAB ...

In new Nature paper, Raze Therapeutics co-founder David Sabatini discovers role for 1C metabolism in glioblastoma

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance ...

Raze Therapeutics Appoints Mark Manfredi as Chief Scientific Officer

Dr. Manfredi joins Raze with nearly two decades of experience in cancer biology ...

all portfolio news